文献速递泌尿生殖腹部PETMRCT

盆腔PSMA-PET/MR与全身PSMA-PET/CT在前列腺癌初始评估中的比较:一项概念验证研究

Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
PubMed 文献 · Eur Radiol · 2019-07-22

前瞻性纳入140例活检证实前列腺癌患者,先后行盆腔PSMA-PET/MR与全身PSMA-PET/CT,比较病灶一致性。两者对前列腺内病灶(K=0.85)和盆腔淋巴结(K=0.98)一致性很好,对骨转移好(K=0.76),对包膜侵犯(K=0.25)和精囊受累(K=0.31)一致性一般;盆腔PSMA-PET/MR在评估包膜侵犯和精囊受累方面优于PET/CT。

要点

  • 盆腔PSMA-PET/MR与全身PSMA-PET/CT对前列腺内PSMA高摄取灶一致性很好(K=0.85)。
  • 两者对盆腔淋巴结一致性很好(K=0.98),对骨转移一致性好(K=0.76)。
  • 对包膜侵犯(K=0.25)和精囊受累(K=0.31)一致性一般,盆腔PSMA-PET/MR优于PET/CT。

核心结论

  • 盆腔PSMA-PET/MR与PET/CT对前列腺内、区域淋巴结和骨PSMA高摄取病灶一致性很好,在包膜侵犯和精囊受累方面优于PET/CT。

研究设计与样本

  • 前瞻性研究,连续纳入组织学活检证实的前列腺癌患者140例(平均年龄67.3±8.2岁),先行盆腔PSMA-PET/MR,再行全身PSMA-PET/CT。

关键影像表现/征象

  • 统计PSMA-PET/CT和PSMA-PET/MR上所有明显PSMA高摄取灶,并结合CT或MR对应分析。
  • 分析前列腺内病灶、包膜侵犯、精囊受累、淋巴结和骨受累。
  • 分析PSMA-PET/MR视野外PSMA-PET/CT上偶然发现和有意义发现。

诊断标准与关键数值

  • 前列腺内PSMA高摄取灶一致性K=0.85。
  • 盆腔淋巴结一致性K=0.98。
  • PSMA高摄取骨转移一致性K=0.76。
  • 前列腺包膜侵犯一致性K=0.25。
  • 精囊受累一致性K=0.31。

临床应用与阅片要点

  • 盆腔PSMA-PET/MR在检测局限性疾病局部延伸方面优于全身PSMA-PET/CT,主要归因于MR的高软组织分辨率。
  • 盆腔PSMA-PET/MR可能有助于组织学活检证实的前列腺癌的初始评估。
  • 需进一步研究评估盆腔PSMA-PET/MR在特定人群筛查和主动监测中的应用。

局限性

  • 需进一步研究评估盆腔PSMA-PET/MR在特定人群筛查和主动监测中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Despite the advantages of prostate-specific membrane antigen (PSMA)-PET/MR over PSMA-PET/CT, its relatively long scanning time and suboptimal PET attenuation correction necessitate careful assessment of the most appropriate setting for this type of study. We assessed lesion agreement between PSMA-PET/MR and PSMA-PET/CT in patients undergoing initial evaluation of prostate cancer.

METHODS: This was a prospective study of consecutive patients with histological biopsy-proven prostate cancer who underwent pelvic PSMA-PET/MR followed by whole-body PSMA-PET/CT. All conspicuous PSMA-avid foci were counted on PSMA-PET/CT and PSMA-PET/MR with CT or MR correlation. Analysis was performed for intra-prostatic lesions, capsular invasion, seminal vesicle involvement and lymph node and bone involvement. Incidental and significant findings seen on PSMA-PET/CT outside the PSMA-PET/MR field of view were also analysed. Agreements between PSMA-PET/CT and PSMA-PET/MR findings were performed using Cohen's kappa test.

RESULTS: Image analysis was performed on 140 patients (mean age, 67.3 ± 8.2 years). Agreement between PSMA PET/CT and PSMA-PET/MR was very good for intra-prostatic PSMA-avid foci (K = 0.85) and pelvic lymph nodes (K = 0.98), good for PSMA-avid bone metastases (K = 0.76) and fair for prostatic capsular invasion (K = 0.25) and seminal vesicle involvement (K = 0.31). Twelve patients (8.5%) had incidental findings and two patients (1.4%) had clinically significant findings.

CONCLUSION: Limited pelvic PSMA-PET/MR has very good agreement with PET/CT regarding PSMA-avid prostatic, regional lymph nodes and bone lesions, and is superior to PET/CT with regard to capsular invasion and seminal vesicle involvement.

KEY POINTS: • Limited pelvic PSMA-PET/MR is superior to whole-body PSMA-PET/CT in detecting extensions of localised disease, mainly due to the high soft tissue resolution of MR. • Limited pelvic PSMA-PET/MR may be useful for initial evaluation of histological biopsy-proven prostate cancer. • Further studies are warranted to evaluate limited pelvic PSMA-PET/MR for screening and active surveillance in selected populations.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Domachevsky L, Bernstine H, Goldberg N, et al. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study. Eur Radiol. 2019. PMID: 31332559. doi:10.1007/s00330-019-06353-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。